
    
      The study duration per participant will include a period to assess eligibility (screening
      period) of up to approximately 4 weeks (28 days), a treatment period and an End-of-Treatment
      (EOT) visit around 30 days after the last administration of IMP, and at least one follow-up
      (FU) visit after the EOT visit.
    
  